Search This Blog

Friday, November 8, 2024

2 Iranians busted in NY, 1 still on the loose in plot to stalk, kill Trump ordered by Tehran

 The Iranian government instructed one of its agents to stalk and assassinate former President Donald Trump this past September, according to a bombshell indictment unsealed by Manhattan federal prosecutors Friday.

The indictment, which charges Iranian Farhad Shakeri and two New Yorkers with murder for hire and conspiracy, states that an unnamed official in Iran’s notorious Islamic Revolutionary Guard Corps (IRGC) instructed Shakeri in the final weeks of the 2024 campaign to “focus on surveilling, and, ultimately, assassinating, former President of the United States, Donald J. Trump.”

Prosecutors say that when Shakeri noted that the plot would “cost a ‘huge’ amount of money,” the IRGC official said that “we have already spent a lot of money … [s]o the money’s not an issue.”

In a phone conversation with an FBI agent, Shakeri said he was instructed by the IRGC on Oct. 7 of this year to have a plan in place to kill Trump “within seven days.”

If Shakeri did not meet his deadline, the IRGC contact allegedly said, the hit on Trump would be postponed until after the election, which Tehran  assessed that the Republican nominee would lose “and, afterward, it would be easier to assassinate [him].”

00:00
04:36
The Iranian government instructed one of its agents to stalk and assassinate former President Donald Trump this past September, according to a bombshell indictment.AP
Shakeri told the FBI he didn’t plan to propose a sceme to murder Trump within the seven days the official had requested, according to the complaint.

The charges were unsealed three days after Trump, 78, defeated Vice President Kamala Harris to become the 47th president-elect. It is the latest example of what officials have described as ongoing efforts by Iran to target Trump and other current and former government officials on US soil.

According to the indictment, an unnamed official in Iran’s notorious Islamic Revolutionary Guard Corps instructed Shakeri to “focus on surveilling, and, ultimately, assassinating, former President of the United States, Donald J. Trump” in the final weeks of the 2024 campaign.Department of Justice

The indictment, which refers to the president-elect as “Victim-4,” charges Shakeri, 51; Brooklyn native Carlisle Rivera, 49; and Staten Islander Jonathan Loadholt, 36, with murder-for-hire, conspiracy to commit murder-for-hire, and money laundering conspiracy.

Rivera and Loadholt were ordered held pending trial Thursday by US Magistrate Judge Jennifer Willis. 

The indictment charges Iranian Farhad Shakeri and two New Yorkers with murder for hire and conspiracy, reports say.Department of Justice

Shakeri, who is believed to be in Iran and out of the reach of American justice, is also charged with conspiring to violate US sanctions against Iran, providing material support to a foreign terrorist organization, and conspiracy to the same. 

“Actors directed by the Government of Iran continue to target our citizens, including President-elect Trump, on US soil and abroad,” Manhattan US Attorney Damian Williams said in a statement Friday. “This has to stop. Today’s charges are another message to those who continue in their efforts — we will remain unrelenting in our pursuit of bad actors, no matter where they reside, and will stop at nothing to bring to justice those who harm our safety and security.”

The indictment details that Shakeri was born in Afghanistan and emigrated to the US as child, but was deported in 2008 after serving a 14-year prison sentence for robbery. During his time behind bars, Shakeri met Rivera and Loadholt, later recruiting them to be hitmen

The feds say Shakeri initially tasked his cohorts with killing Iranian-American activist and journalist Masih Alinejad, an outspoken critic of the Tehran regime who has been targeted for assassination in the past by Iran. 

Rivera and Loadholt pursued Alinejad for nine months, according to the indictment, with the former hit man allegedly complaining to Shakeri at one point: “This b—h is hard to catch, bro.”

Alinejad is not named in the indictment, but the court documents include details of her public schedule which match up with her public itinerary.

Other would-be targets of the trio included two “Jewish businesspeople residing in New York City,” according to the complaint. Shakeri claimed the IRGC had provided pictures of both potential victims, which “appeared to come from social media and which indicated [their] support for Israel.”

Shakeri also told the FBI that he had been instructed by Iran to plot a mass shooting targeting Israeli tourists in Sri Lanka — which prompted the US and Israeli governments to issue a travel warning for the island nation on Oct. 23.

This is a developing story. Please check back for more updates.

https://nypost.com/2024/11/08/us-news/iranian-agent-instructed-to-stalk-assassinate-trump-by-tehran-bombshell-indictment-reveals/

Eisai Cuts Fiscal 2024 Guidance for Biogen-Partnered Leqembi as Sales Disappoint

 

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy is being held back by barriers such as coverage, infusion centers and time to diagnosis.

Eisai on Friday lowered its full-year revenue forecast for Biogen-partnered Alzheimer’s therapy Leqembi amid continued growing pains with the drug’s launch in the U.S. and in international markets.

The Japanese pharma now expects Leqembi to bring in nearly $280 million in the fiscal year 2024, down from its previous guidance of around $370 million. Eisai anticipates the U.S. market to account for much of the Leqembi sales this fiscal year, with projected revenue of $170 million in the country. Outside the U.S., Leqembi is approved in Japan, where it launched in December 2023, and in China, where it hit the market in June 2024.

The downward adjustment to Leqembi’s sales forecast, released Friday as part of its six-month financial report for the current fiscal year, comes as the antibody continues to struggle.

In the first half of the fiscal year, Leqembi brought in approximately $110 million “with growth exceeding business plan,” according to Eisai’s presentation. In Q3, Leqembi generated $67 million in revenue, which handily beat the $50 million consensus estimate.

However, Leqembi’s uptake is still “underwhelming” overall, contends Truist Securities analyst Srikripa Devarakonda.

“Investors have grown impatient and skeptical, in light of how long it’s been taking for the launch of the first ever disease modifying AD drug to really take off,” Stifel analyst Paul Matteis wrote in a note to investors. Jefferies analyst Michael Yee called Leqembi’s Q3 revenue “modest,” noting that while its overseas sales exceeded expectations, its launch in the U.S. “remains bumpy.”

Still, the bulk of Leqembi’s sales came from the U.S., where confirmatory testing for amyloid-beta is no longer a limiting factor. In October 2023, the Centers for Medicare and Medicaid Services removed its upper limit to the number of amyloid-beta PET testing that it would reimburse. This decision led to what Eisai called a “sharp increase” in confirmatory testing.

Despite this improvement in coverage, “infrastructure remains a constraint,” according to BMO Capital Markets analyst Evan Seigerman, who in an investor note said that there continues to be “barriers” to Leqembi’s robust growth such as “infusion centers, neurologists, and time to diagnose.”

Nevertheless, analysts see reason for optimism. Matteis said that Leqembi’s performance in recent months “have been very supportive” and that “something may actually be materializing here.” William Blair analyst Myles Minter similarly noted that “demand is not the limiting factor” for Leqembi and that the company is currently working to accelerate treatment uptake.

Biogen and Eisai also touted an increase in prescribers and eligible patients for Leqembi. According to Eisai’s presentation, there are currently 10,000 patients in the U.S. who are eligible for treatment. Of those, around 4,000 patients have already been dosed, with the remaining 6,000 in line to start treatment. These developments “could translate to future sales growth once the administrative hurdles are better addressed,” Yee said.

https://www.biospace.com/business/eisai-cuts-fiscal-2024-guidance-for-biogen-partnered-leqembi-as-sales-disappoint-analysts

Pfizer Makes $1B Commitment in China to Boost Innovation, Targets Chinese Market

 

The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country into the company’s global strategy.

Pfizer earlier this week announced that it will pump $1 billion into its China operations, with the aim of improving innovation in the country’s biotech ecosystem, according to multiple media reports.

“We have developed … a five-year plan. We call it ‘China 2030,’” Pfizer China President Jean-Christophe Pointeau said in a promotional video. “We will invest $1 billion, which is about 7.5 billion RMB, in China for the period of five years.” The investment was revealed during the seventh China International Import Expo in Shanghai, according to an online translation of a report from Chinese language news outfit SINA.

With the capital injection, Pfizer hopes to accelerate biotech innovation in the country, with the goal of developing the local biotech industry and helping the Chinese government meet its Healthy China 2030 goal—a state-sponsored initiative that seeks to leverage domestic innovation to expand Chinese industry, boost health equity and the importance of healthy diets and exercise. Several international bodies, including the World Health Organization, support the Healthy China 2030 initiative.

Under Pfizer’s five-year strategic plan, the company will build a new R&D facility in Beijing to help develop its innovative therapies in China, while incorporating the country into its global strategy and opening up participation in clinical trials, according to SINA.

The money will also help Pfizer improve the diagnostic capacity and treatment standards of China’s healthcare system.

In addition to the $1 billion investment, Pfizer on Thursday entered into a strategic agreement with Beijing Tianguangshi Biotechnology and Kangyuan Bochuang Biotechnology to advance therapies for multiple myeloma, according to a digitally translated news release. Details of the deal were sparse—the companies did not reveal specific considerations for the contract, its timeline and the platforms or mechanisms of actions that they plan to leverage.

These latest Pfizer investments in China come as it continues to face pressure from activist investor Starboard Value, which last month took a $1 billion stake in the company, with an eye toward turning the business around. Starboard contends that current CEO Albert Bourla has failed to deliver financial returns to investors, abandoning Pfizer’s typically disciplined spending and smart investment in high-potential drugs.

Analysts, however, have generally taken Bourla’s side with many opining that the CEO has taken sufficient steps to soften the blow of the steep decline in COVID-19 demand. Last week, the company reported a Q3 beat, delivering $17.7 billion in revenue in the quarter, versus the analyst consensus of $14.92 billion—in a much-needed win for Bourla.

https://www.biospace.com/business/pfizer-makes-1b-commitment-in-china-to-boost-innovation-target-chinese-market